MONTREAL, June 28, 2011 (GLOBE NEWSWIRE) -- A5 Laboratories Inc., (OTCBB:AFLB) - a Biotechnology company by developing novel immune therapeutic applications of interferon therapy to treat cancer and infectious diseases, is pleased to announce the impending move of its cell culture and microbiology department of the C.R.O. division into the state-of-the-art facilities located in the Industrial Partnership Facility at the Biotechnology Research Institute in Montreal.
This move will hasten the development of A5 Laboratories' proprietary methods for the production of animal interferon's. The CRO division will aid A5 Labs in its clinical testing development while expanding its own client base in the areas of chemical analysis and microbiological testing.
The close proximity to renowned scientists in cell culture, protein purification, chemistry and biotechnology will allow A5 Labs to draw on this expertise as it moves toward commercialization of its products. Ready access to BRI's specialized equipment and infrastructure will further enable this goal.
"We are excited about the move of our cell culture and microbiology department of the C.R.O. division into the state–of–art facilities at the Biotechnology Research Institute. The technology that will now be available to A5 Labs, will be a major step forward in the commercialization of A5 Labs products," stated Dr. Richard Azani, president and CEO of A5 Laboratories.
More information about the Company is available on its corporate website at www.a5labs.com
About A5 Labs: AFLB.ob A5 Labs is a contract research based organization servicing the pharmaceutical and biotechnology companies in North America. The company utilizes its research capabilities to license and acquire novel biotechnology products for development and commercialization. For more information about the Company is available at its corporate website at www.a5labs.com for more information visit their corporate fact sheet http://premierstocks.tv/images/company_links/A5.pdf
Safe Harbor Statement:
Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to A5 or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of A5's products, the competitive environment within the industry, the ability of A5 to continue to expand its operations, the level of costs incurred in connection with A5's expansion efforts, economic conditions in the industry and the financial strength of A5's customers and suppliers. A5 does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.
CONTACT: Investor inquiries: Premier Media Service Inc. Kelly Black Office: 1-480-649-8224 or 1-866-465-6551 email@example.com